Nippon India Pharma Fund Regular Growth
EquitySector - HealthcareVery High Risk
Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹8,648 Cr
Expense Ratio
1.82%
ISIN
INF204K01968
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
05 Jun 2004
About this fund
As of 05-Sep-24, it has a Net Asset Value (NAV) of ₹521.94, Assets Under Management (AUM) of 8647.95 Crores, and an expense ratio of 1.82%.
- Nippon India Pharma Fund Regular Growth has given a CAGR return of 21.57% since inception.
- The fund's asset allocation comprises around 97.40% in equities, 0.00% in debts, and 2.60% in cash & cash equivalents.
- You can start investing in Nippon India Pharma Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+50.10%
+54.79% (Cat Avg.)
3 Years
+18.17%
+18.09% (Cat Avg.)
5 Years
+29.66%
+29.12% (Cat Avg.)
10 Years
+16.36%
+15.75% (Cat Avg.)
Since Inception
+21.57%
— (Cat Avg.)
Portfolio Summaryas of 31st August 2024
| Equity | ₹8,423.23 Cr | 97.40% |
| Others | ₹224.72 Cr | 2.60% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹1,194.34 Cr | 13.81% |
| Lupin Ltd | Equity | ₹717.69 Cr | 8.30% |
| Divi's Laboratories Ltd | Equity | ₹688.09 Cr | 7.96% |
| Cipla Ltd | Equity | ₹513.02 Cr | 5.93% |
| Dr Reddy's Laboratories Ltd | Equity | ₹492.22 Cr | 5.69% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹449.45 Cr | 5.20% |
| Ajanta Pharma Ltd | Equity | ₹311.16 Cr | 3.60% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹276.26 Cr | 3.19% |
| Gland Pharma Ltd | Equity | ₹275.78 Cr | 3.19% |
| Aurobindo Pharma Ltd | Equity | ₹267.21 Cr | 3.09% |
| Abbott India Ltd | Equity | ₹260.86 Cr | 3.02% |
| Zydus Lifesciences Ltd | Equity | ₹253.85 Cr | 2.94% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹249.85 Cr | 2.89% |
| Triparty Repo | Cash - Repurchase Agreement | ₹230.69 Cr | 2.67% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹228.61 Cr | 2.64% |
| Mankind Pharma Ltd | Equity | ₹224.1 Cr | 2.59% |
| Medplus Health Services Ltd | Equity | ₹209.02 Cr | 2.42% |
| Pfizer Ltd | Equity | ₹193.02 Cr | 2.23% |
| Narayana Hrudayalaya Ltd | Equity | ₹190.5 Cr | 2.20% |
| Torrent Pharmaceuticals Ltd | Equity | ₹175.43 Cr | 2.03% |
| Alkem Laboratories Ltd | Equity | ₹171.17 Cr | 1.98% |
| Sanofi India Ltd | Equity | ₹156.79 Cr | 1.81% |
| Fortis Healthcare Ltd | Equity | ₹154.5 Cr | 1.79% |
| Thyrocare Technologies Ltd | Equity | ₹152.18 Cr | 1.76% |
| Dr. Lal PathLabs Ltd | Equity | ₹111.07 Cr | 1.28% |
| Syngene International Ltd | Equity | ₹97.72 Cr | 1.13% |
| Orchid Pharma Ltd | Equity | ₹94.76 Cr | 1.10% |
| Sanofi Consumer He | Equity | ₹80.61 Cr | 0.93% |
| Indoco Remedies Ltd | Equity | ₹66.32 Cr | 0.77% |
| Emcure Pharmaceuticals Ltd | Equity | ₹42.31 Cr | 0.49% |
| AstraZeneca Pharma India Ltd | Equity | ₹42.21 Cr | 0.49% |
| HealthCare Global Enterprises Ltd | Equity | ₹34.86 Cr | 0.40% |
| Concord Biotech Ltd | Equity | ₹24.89 Cr | 0.29% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹23.38 Cr | 0.27% |
| Net Current Assets | Cash | ₹-6.03 Cr | 0.07% |
| Cash Margin - Ccil | Cash - Collateral | ₹0.05 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
43.21%
Mid Cap Stocks
33.87%
Small Cap Stocks
18.90%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹8,342.62 Cr | 96.47% |
Risk & Performance Ratios
Standard Deviation
This fund
15.35%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.80
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Fund Managers
Sailesh Raj Bhan
Since April 2005
Kinjal Desai
Since May 2018
Additional Scheme Detailsas of 31st August 2024
ISIN | INF204K01968 | Expense Ratio | 1.82% | Exit Load | 1.00% | Fund Size | ₹8,648 Cr | Age | 05 Jun 2004 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
About the AMC
Total AUM
₹5,54,956 Cr
Address
4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013
Other Funds by Nippon India Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Nippon India Pharma Fund Regular Growth?
What are the returns of Nippon India Pharma Fund Regular Growth?
What is the portfolio composition of Nippon India Pharma Fund Regular Growth?
Who manages the Nippon India Pharma Fund Regular Growth?
- Sailesh Raj Bhan
- Kinjal Desai
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.